Lilly picks AmerisourceBergen for U.S. commercial rollout of COVID-19 antibody therapy

Aug. 09, 2022 11:26 AM ETEli Lilly and Company (LLY)ABC, ABCLBy: Dulan Lokuwithana, SA News Editor2 Comments

Eli Lilly and Company Research Laboratories. Lilly makes Medicines and Pharmaceuticals.

jetcityimage/iStock Editorial via Getty Images

  • Eli Lilly (NYSE:LLY) announced that the FDA had updated the authorization granted for its COVID-19 antibody therapy bebtelovimab allowing its commercial availability from next week through the drug distributor AmerisourceBergen (ABC).
  • Per the previous authorization, the U.S. government controlled the domestic distribution of bebtelovimab.
  • According to the company, with the updated clearance, bebtelovimab will be commercially available for states/territories, hospitals, and other healthcare providers from Aug. 15.
  • Lilly (LLY) has selected AmerisourceBergen Specialty Distribution as the sole distributor for the rollout.
  • A monoclonal antibody, bebtelovimab, was discovered by AbCellera Biologics (ABCL), which later licensed it to Lilly (LLY) for further studies.
  • Recently, the U.S. agreed to procure extra 150K doses of bebtelovimab for approximately $275M under a modified purchase agreement with the company.

Recommended For You

Comments (2)

To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.